Skip to main content
Clinical Trials/PER-100-03
PER-100-03Completed未知

RANDOMIZED STUDY OF COADYUVANT CHEMOTHERAPY WITH STANDARD REGIMES OF CYCLOPHOSPHAMIDE, METHOTREXATE AND FLUORURACILO - (CMF) OR DOXORUBICINE AND CICLOFOSFAMIDA - (AC) VERSUS CAPECITABINE IN WOMEN 65 YEARS OF AGE OR MORE POSITIVE OR NEGATIVE NODULES WITH HIGH-RISK BREAST CANCER.

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 sites0 target enrollmentStarted: February 6, 2004Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
0 to 0 (—)

Inclusion Criteria

  • Patients with operable, histologically confirmad adenocarcinoma of the female breast.
  • STNM Stage: T1-3, N1. MO or T2, NO, MO if a primary lesion > 3 cm.
  • or T3. NO. MO
  • Age 65 years or older
  • Performance status 0-2 (Common Toxicity Criteria).

Exclusion Criteria

  • Not provided

Investigators

Sponsor
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),

Similar Trials